» Articles » PMID: 20349162

Elevated Osteopontin Expression and Proliferative/apoptotic Ratio in the Colorectal Adenoma-dysplasia-carcinoma Sequence

Overview
Specialty Oncology
Date 2010 Mar 30
PMID 20349162
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer progression is characterized by altered epithelial proliferation and apoptosis and by changed expression of tumor development regulators. Our aims were to determine the proliferative/apoptotic epithelial cell ratio (PAR) in the adenoma-dysplasia-carcinoma sequence (ADCS), and to examine its association with osteopontin (OPN), a previously identified protein product related to cancer development. One mm diameter cores from 13 healthy colons, 13 adenomas and 13 colon carcinoma samples were included into a tissue microarray (TMA) block. TUNEL reaction and Ki-67 immunohistochemistry were applied to determine the PAR. The osteopontin protein was also immunodetected. Stained slides were semiquantitatively evaluated using digital microscope and statistically analyzed with logistic regression and Fisher's exact test. The PAR continuously increased along the ADCS. It was significantly (p < 0.001) higher in cancer epithelium (8.84 ± 7.01) than in adenomas (1.40 ± 0.78) and in normal controls (0.89 ± 0.21) (p < 0.001). Also, significant positive correlation was observed between elevated PAR and the expression of osteopontin. Cytoplasmic OPN expression was weak in healthy samples. In contrast, cytoplasmic immunoreaction was moderately intensive in adenomas, while in colon cancer strong, diffuse cytoplasmic immune staining was detected. Increasing PAR and OPN expression along ADCS may help monitoring colorectal cancer progression. The significantly elevated OPN protein levels we found during normal epithelium to carcinoma progression may contribute to the increased fibroblast-myofibroblast transition determining stem cell niche in colorectal cancer.

Citing Articles

IS THERE A CLINICAL PATHOLOGICAL CORRELATION OF COLORECTAL ADENOCARCINOMA WITH THE IMMUNOHISTOCHEMICAL EXPRESSION OF OPN AND ABCB5?.

Castoldi D, Malafaia O, Santos-Neto P, Postiglioni T, Vasconcelos C, Bremer F Arq Bras Cir Dig. 2021; 33(4):e1569.

PMID: 33759959 PMC: 7983527. DOI: 10.1590/0102-672020200004e1569.


Expression of Extracellular Matrix-Related Genes and Their Regulatory microRNAs in Problematic Colorectal Polyps.

Zlajpah M, Bostjancic E, Tepes B, Zidar N Cancers (Basel). 2020; 12(12).

PMID: 33322258 PMC: 7764749. DOI: 10.3390/cancers12123715.


Alteration of the abundance of in the gut along the adenoma-carcinoma sequence.

Xu J, Yang M, Wang D, Zhang S, Yan S, Zhu Y Oncol Lett. 2020; 20(4):106.

PMID: 32831925 PMC: 7439112. DOI: 10.3892/ol.2020.11967.


Curcumin Veto the Effects of Osteopontin (OPN) Specific Inhibitor on Leukemic Stem Cell Colony Forming Potential via Promotion of OPN Overexpression.

Mohammadi S, Ghaffari S, Shaiegan M, Nikogoftar Zarif M, Nikbakht M, Alimoghaddam K Int J Hematol Oncol Stem Cell Res. 2016; 10(3):120-9.

PMID: 27489587 PMC: 4969556.


Anti-apoptotic effects of osteopontin through the up-regulation of Mcl-1 in gastrointestinal stromal tumors.

Hsu K, Tsai H, Lin P, Hsu Y, Lu P, Shan Y World J Surg Oncol. 2014; 12:189.

PMID: 24947165 PMC: 4080696. DOI: 10.1186/1477-7819-12-189.

References
1.
Burgess A . Growth control mechanisms in normal and transformed intestinal cells. Philos Trans R Soc Lond B Biol Sci. 1998; 353(1370):903-9. PMC: 1692276. DOI: 10.1098/rstb.1998.0254. View

2.
Huang W, Carlsen B, Rudkin G, Berry M, Ishida K, Yamaguchi D . Osteopontin is a negative regulator of proliferation and differentiation in MC3T3-E1 pre-osteoblastic cells. Bone. 2004; 34(5):799-808. DOI: 10.1016/j.bone.2003.11.027. View

3.
Hawinkels L, Verspaget H, van der Reijden J, van der Zon J, Verheijen J, Hommes D . Active TGF-beta1 correlates with myofibroblasts and malignancy in the colorectal adenoma-carcinoma sequence. Cancer Sci. 2009; 100(4):663-70. PMC: 11158318. DOI: 10.1111/j.1349-7006.2009.01100.x. View

4.
Miyazaki K, Okada Y, Yamanaka O, Kitano A, Ikeda K, Kon S . Corneal wound healing in an osteopontin-deficient mouse. Invest Ophthalmol Vis Sci. 2008; 49(4):1367-75. DOI: 10.1167/iovs.07-1007. View

5.
Bautista D, Xuan J, Hota C, Chambers A, Harris J . Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem. 1994; 269(37):23280-5. View